Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
balapiravir + peginterferon alfa-2a + ribavirin
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
This combination consists of **balapiravir** (a small molecule oral prodrug, code name RO4588161, developed by Roche, also known as R-1626), **peginterferon alfa-2a** (a pegylated recombinant interferon alfa-2a protein, approved for hepatitis C), and **ribavirin** (a nucleoside analogue antiviral). - **Balapiravir** is a prodrug of R1479, designed to inhibit the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, halting viral RNA replication. - **Peginterferon alfa-2a** modulates immune response to enhance clearance of HCV-infected cells. - **Ribavirin** is a guanosine analogue that inhibits viral RNA synthesis and viral mRNA capping, with a broad antiviral mechanism. This triple combination was developed for chronic HCV infection but discontinued due to lack of efficacy and unacceptable toxicity of balapiravir at higher doses, such as lymphopenia. Primary indication: hepatitis C virus infection[1][3][5][7][9][2][4][10].
- Other names
- balapiravir + peginterferon alfa-2a + ribavirinR-1626 + peginterferon alfa-2a + ribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on balapiravir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on balapiravir + peginterferon alfa-2a + ribavirin.